- $2.33bn
- $3.71bn
- $2.26bn
- 82
- 62
- 50
- 70
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.9 | ||
| PEG Ratio (f) | 0.24 | ||
| EPS Growth (f) | 293.81% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.1 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 32.17 | ||
| Price to Sales | 1.03 | ||
| EV to EBITDA | 14.68 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 0.59% | ||
| Return on Equity | -1.41% | ||
| Operating Margin | 1.01% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,266.21 | 1,271 | 1,316.31 | 2,280 | 2,259.13 | 2,278.42 | 2,365.08 | 10.04% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +41.82 | -38.17 | +8.21 | n/a | n/a | n/a | +43.32 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needle free IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy product include Portex BLUselect PVC tracheostomy tubes.
Directors
- Vivek Jain CHM (61)
- Brian Bonnell CFO (47)
- Christian Voigtlander COO (53)
- Virginia Sanzone VPR (46)
- Daniel Woolson VPR (44)
- David Greenberg LED (54)
- George Lopez DRC (73)
- Donald Abbey IND (54)
- Elisha Finney IND (59)
- Laurie Hernandez IND
- David Hoffmeister IND (66)
- Kolleen Kennedy IND (61)
- William Seeger IND (70)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 9th, 1992
- Public Since
- March 31st, 1992
- No. of Shareholders
- 44
- No. of Employees
- 14,000
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 24,365,082
- Address
- 951 Calle Amanecer, SAN CLEMENTE, 92673
- Web
- https://www.icumed.com/
- Phone
- +1 9493662183
- Contact
- John Mills
- Auditors
- Deloitte & Touche LLP
Latest News for ICUI
Upcoming Events for ICUI
Q1 2024 ICU Medical Inc Earnings Release
ICU Medical Inc Annual Shareholders Meeting
ICU Medical Inc Annual Shareholders Meeting
Q2 2024 ICU Medical Inc Earnings Release
Similar to ICUI
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
As of Today at 19:11 UTC, shares in ICU Medical are trading at $95.77. This share price information is delayed by 15 minutes.
Shares in ICU Medical last closed at $95.77 and the price had moved by -45.55% over the past 365 days. In terms of relative price strength the ICU Medical share price has underperformed the S&P500 Index by -54.69% over the past year.
The overall consensus recommendation for ICU Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
ICU Medical does not currently pay a dividend.
ICU Medical does not currently pay a dividend.
ICU Medical does not currently pay a dividend.
To buy shares in ICU Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $95.77, shares in ICU Medical had a market capitalisation of $2.33bn.
Here are the trading details for ICU Medical:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ICUI
Based on an overall assessment of its quality, value and momentum ICU Medical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in ICU Medical is $136.00. That is 42.01% above the last closing price of $95.77.
Analysts covering ICU Medical currently have a consensus Earnings Per Share (EPS) forecast of $4.73 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ICU Medical. Over the past six months, its share price has underperformed the S&P500 Index by -24.77%.
As of the last closing price of $95.77, shares in ICU Medical were trading -15.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ICU Medical PE ratio based on its reported earnings over the past 12 months is 17.9. The shares last closed at $95.77.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
ICU Medical's management team is headed by:
- Vivek Jain - CHM
- Brian Bonnell - CFO
- Christian Voigtlander - COO
- Virginia Sanzone - VPR
- Daniel Woolson - VPR
- David Greenberg - LED
- George Lopez - DRC
- Donald Abbey - IND
- Elisha Finney - IND
- Laurie Hernandez - IND
- David Hoffmeister - IND
- Kolleen Kennedy - IND
- William Seeger - IND